Phaseline

Companies › CSPC Mingfule Pharmaceutical (Guangzhou)

CSPC Mingfule Pharmaceutical (Guangzhou): clinical trials, targets and expected readouts

1 active drug program in 34 registered trials: 22 Phase 3, 7 Phase 2, 4 Phase 4, 1 Phase 1; Neurology, Cardiovascular; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tenecteplase
Tissue-type plasminogen activator exogenous protein
PLATPhase 3Acute Ischemic Stroke; ST-segment Elevation Myocardial Infarction (STEMI); Ischemic Stroke; Stroke, Ischemic …Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06814964TenecteplasePhase 1Intraventricular HemorrhageCardiovascularMay 2025
NCT06414499TenecteplasePhase 3Minor Ischemic StrokeNeurologyJul 2026
NCT06658197TenecteplasePhase 3Stroke, IschemicNeurologyDec 2026
NCT06904911TenecteplasePhase 2Acute Ischemic Stroke From Large Vessel OcclusionNeurologyDec 2026
NCT03998319TenecteplasePhase 3STEMICardiovascularDec 2026
NCT06749834TenecteplasePhase 3Acute Ischemic StrokeNeurologyDec 2026
NCT06954155TenecteplasePhase 3StrokeNeurologyFeb 2027
NCT06868511TenecteplasePhase 3Deep Intracerebral Hemorrhage (ICH)NeurologyMar 2027
NCT07047014TenecteplasePhase 3Stroke, IschemicNeurologyMar 2027
NCT05199662TenecteplasePhase 3Ischemic Stroke, AcuteNeurologyJul 2027
NCT05199194TenecteplasePhase 3Stroke, IschemicNeurologyJul 2027
NCT05892510TenecteplasePhase 2Ischemic Stroke, AcuteNeurologyAug 2027
NCT07201688TenecteplasePhase 3Acute Ischemic StrokeNeurologySep 2027
NCT07357987TenecteplasePhase 3Ischemic StrokeNeurologySep 2027
NCT06987305TenecteplasePhase 3Stroke, Acute IschemicNeurologyOct 2027
NCT06769256TenecteplasePhase 4ST-segment Elevation Myocardial Infarction (STEMI)CardiovascularDec 2027
NCT07375953TenecteplasePhase 2Ischemic StrokeNeurologyDec 2027
NCT07375966TenecteplasePhase 2Ischemic StrokeNeurologyDec 2027
NCT07203625TenecteplasePhase 4Acute Ischemic StrokeNeurologyDec 2027
NCT06994975TenecteplasePhase 3Acute Ischemic StrokeNeurologyMar 2028
NCT07253181TenecteplasePhase 3Acute Ischemic StrokeNeurologyMar 2028
NCT05105633TenecteplasePhase 2Basilar Artery OcclusionCardiovascularMay 2028
NCT06949228TenecteplasePhase 2Ischemic StrokeNeurologyMay 2028
NCT07092709TenecteplasePhase 3Acute Ischemic StrokeNeurologySep 2028
NCT07606807TenecteplasePhase 3Acute Ischemic StrokeNeurologyDec 2028
NCT07475949TenecteplasePhase 3Acute Ischemic StrokeNeurologyDec 2028
NCT07302854TenecteplasePhase 2Acute Ischemic StrokeNeurologyDec 2028
NCT06878066TenecteplasePhase 3StrokeCardiovascularDec 2028
NCT06571149TenecteplasePhase 4Ischemic StrokeNeurologyJan 2029
NCT07668323TenecteplasePhase 3Medium Vessel OcclusionNeurologyJan 2029
NCT07748039TenecteplasePhase 3Acute Ischemic StrokeNeurologyMar 2029
NCT06010628TenecteplasePhase 4Stroke, IschemicNeurologyDec 2029
NCT06352632TenecteplasePhase 3StrokeNeurologySep 2034
NCT06352632TenecteplasePhase 3StrokeNeurologySep 2034

Targets

PLAT (1)

Companies with the same targets

Boehringer Ingelheim

Companies built like this

Shenzhen Ausa Pharmed Eidos Therapeutics, a BridgeBio company Bracco Diagnostics THPharm Ever Neuro Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.